Renibus Announces Leadership Transition
SOUTHLAKE, Texas, March 21, 2024 /PRNewswire/ -- Renibus Therapeutics® ("Renibus"), a clinical-stage biopharmaceutical company focusing on the prevention and treatment of cardio-renal and metabolic diseases, today announced a transition in its leadership structure. As part of this change, Frank Stonebanks, former co-CEO, has left the company to pursue new opportunities. Renibus wishes Mr. Stonebanks the best in his future endeavors. Jeffrey Keyser, RPh, JD, PhD, co-founder and former co-CEO, has been appointed President and CEO of Renibus.
- SOUTHLAKE, Texas, March 21, 2024 /PRNewswire/ -- Renibus Therapeutics® ("Renibus"), a clinical-stage biopharmaceutical company focusing on the prevention and treatment of cardio-renal and metabolic diseases, today announced a transition in its leadership structure.
- Jeffrey Keyser, RPh, JD, PhD, co-founder and former co-CEO, has been appointed President and CEO of Renibus.
- Prior to co-founding Renibus, Dr. Keyser invented the Mucinex product line for Adams Respiratory Therapeutics, Inc. and co-founded ZS Pharma, Inc. (acquired by Astra Zeneca Plc).
- His leadership has been instrumental in Renibus' success to date and he is well positioned to lead the company into its next phase of growth and innovation.